Liver fibrosis.
Conditions
Interventions
Intervention 1: Intervention group:Nanocurcumin 40 mg Exir Nano Sina (twice a day),The patients will be received 1 capsule of 40 mg of nano curcumin two times daily for 4 months. Intervention 2: Cont
Sponsors
Yazd University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 70 Years
Inclusion criteria
Inclusion criteria: patients between 30 and 70 years of age with liver fibrosis F=2 referring to the liver and digestive consultation and treatment clinic
Exclusion criteria
Exclusion criteria: History of alcohol intake or current intake of alcohol evidence of other forms of chronic and acute liver diseases (such as viral hepatitis B, C etc), biliary disease, known autoimmune hepatitis and hereditary disorders affecting the liver (storage disease of iron, copper etc) current pregnancy or breastfeeding Use of hepatotoxic medication current Lung and kidney disease Drug abuse, history of cancer Treatment with anti-inflammatory, corticosteroids and hormones medication Use of weight loss medication or diets Intolerance or allergy to the supplement Unwillingness to participate in the study New diet Changes in the patient's medications Patients with current warfarin medications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver fibrosis. Timepoint: Before and 16 weekes after the intervention. Method of measurement: Determining the amount of liver tissue fibrosis by using Elastography (2D Shear Wave Elastography- SWE).;Liver steatosis. Timepoint: Before and 16 weekes after the intervention. Method of measurement: Determining the amount of liver tissue steatosis by using Elastography (2D Shear Wave Elastography- SWE). | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver function tests (LDH ?ALT?AST?Albumin ?GGT ?ALP?Bilirubin Total and Bilirubin Direct). Timepoint: Baseline and 16 weeks. Method of measurement: lab kit.;Lipid profile (HDL-c, LDL-c, TG, TC). Timepoint: Baseline and 16 weeks. Method of measurement: lab kit.;Fasting glucose, serum insulin. Timepoint: Baseline and 16 weeks. Method of measurement: lab kit.;Inflammatory factors Hs-CRP and ESR. Timepoint: Baseline and 16 weeks. Method of measurement: lab kit.;Anthropometric indicators (weight). Timepoint: Baseline and 16 weeks. Method of measurement: Weight of a person with light clothes and without shoes (Kg).;Anthropometric indicators (waist circumference). Timepoint: Baseline and 16 weeks. Method of measurement: Waist size in the distance between the hip bone and the last rib (cm).;Anthropometric indices (body mass index). Timepoint: Baseline and 16 weeks. Method of measurement: The ratio of weight (in kilograms) to the square of height (in meters).;Anthropometric indicators (fat mass and fat-free mass). Timepoint: Baseline and 16 weeks. Method of measurement: Using the body composition device.;Blood pressure. Timepoint: Baseline and 16 weeks. Method of measurement: Measurement of systolic and diastolic blood pressure (mm Hg). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHadis Gerami
Yazd University of Medical Sciences
Outcome results
None listed